Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia.
Ontology highlight
ABSTRACT: Despite significant progress over the last few decades in the treatment of acute myeloid leukemia (AML), there still remains a major unmet medical need for this disease. Immunotherapy approaches for redirecting pan CD3+ T cells to target leukemia blasts have shown limited efficacy in clinical trials and often accompanied with severe toxicity in AML patients. We designed an alternative engager molecule (Anti-TRGV9/anti-CD123), a bispecific antibody that can simultaneously bind to the Vγ9 chain of the Vγ9Vδ2+ γδ T cell receptor and to AML target antigen, CD123, to selectively recruit Vγ9+ γδ T cells rather than pan T cells to target AML blasts. Our results suggest that prototypic bispecific antibodies (a) selectively activate Vγ9+ γδ T cells as jud
SUBMITTER: Ganesan R
PROVIDER: S-EPMC8324575 | biostudies-literature | 2021 Aug
REPOSITORIES: biostudies-literature
ACCESS DATA